SLS Earnings Date: Nov 18, 2026 (Estimated) — SELLAS Life Sciences Group, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is SLS's next earnings date?
SELLAS Life Sciences Group, Inc. (SLS) is expected to report Q3 2026 earnings on Wednesday, November 18, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.05.
How did SLS do in its last earnings report?
In its most recent report on Aug 11, 2026 (Q2 2026), SELLAS Life Sciences Group, Inc. posted EPS of -$0.05 versus the -$0.04 estimate, a miss of 25.0%. Revenue was $0. The stock's 1-day post-earnings move was +6.5%.
How much does SLS stock move after earnings?
SLS beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.9% (up or down) in the day after earnings.
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -0.04 | -0.05 | -25.00% | $0 | ❌ Miss | +6.52% | +18.55% | +22.08% |
| 2026-05-12 | Q1 2026 | -0.06 | -0.05 | +16.67% | $0 | ✅ Beat | +25.10% | +45.40% | +48.47% |
| 2026-03-19 | Q4 2025 | -0.06 | -0.05 | +16.67% | $0 | ✅ Beat | -8.46% | -4.81% | -4.04% |
| 2025-11-12 | Q3 2025 | -0.08 | -0.06 | +25.00% | $0 | ✅ Beat | -2.01% | +2.01% | +36.24% |
| 2025-08-12 | Q2 2025 | -0.08 | -0.07 | +12.50% | $0 | ✅ Beat | -3.73% | +5.59% | +17.39% |
| 2025-03-20 | Q4 2024 | -0.11 | -0.08 | +27.27% | $0 | ✅ Beat | -0.83% | -4.13% | +6.61% |
| 2024-11-13 | Q3 2024 | -0.13 | -0.10 | +23.08% | $0 | ✅ Beat | +0.00% | -2.36% | -31.33% |
| 2024-08-13 | Q2 2024 | -0.17 | -0.13 | +23.53% | $0 | ✅ Beat | +0.84% | +10.08% | +11.76% |
Showing last 8 quarters.